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A 41 year-old female patient came to our outpatient clinic complaining of 
long-time episodes of headache. The pain was intense, migrainous, without 
aura, and with variable periodicity. During her life she was seen by some 
physicians without an appropriate diagnosis and used different therapeutic 
modalities without satisfactory results. She had no other health problems. Her 
family history was unremarkable, except for history of stroke and migraine in 
some of her relatives. An MRI showed abundant T2-weighted hyperintensities 
in subcortical white matter, with involvement of the temporal lobe (figure 1). 
A DNA test for NOTCH3 gene in the patient, but not in the family, revealed a 
mutation fully compatible with CADASIL disease.
Cerebral autosomal-dominant arteriopathy with subcortical infarcts and 
leukoencephalopathy (CADASIL), Online Mendelian Inheritance in Man (OMIM 
#125310), is a rare form of familial cerebrovascular disorder. It is caused by 
mutation of the NOTCH3 gene, located on the short arm of chromosome 
19 (19p13.2-p13.1), and is the most common form of hereditary stroke 
disorder1-5. CADASIL is characterized by migrainous headaches, with or 
without aura, and relapsing strokes. About 10% of patients might develop 
seizures. Strokes are characterized by transient ischemic attacks or lacunar 
strokes and these are the most consistent clinical findings. With progression 
of disease, patients may also develop different forms of neuropsychiatric 
symptoms. In advanced cases, patients might evolve to a vascular dementia 
of subcortical type. The disease affects relatively young adults of both sexes. 
Family history suggests an autosomal dominant pattern1-5. More than 95% 
of patients present mutations in the NOTCH3 gene, which encodes a single 
pass transmembrane protein belonging to an evolutionarily conserved NOTCH 
receptor family1,4. After ligand binding, the intracellular domain translocates to 
the nucleus and activates transcription factors. The Notch signaling pathway 
plays a central role in the development and maturation of organs. The protein 
product Notch3 is critical for vascular smooth muscle cell differentiation and 
vascular development1,3,4. In adults, Notch3 expression is limited to vascular 
muscle cells. Mutations in the NOTCH3 gene result in abnormal protein that 
deposits and accumulates in the cytoplasmic membrane of vascular muscle 
cells and pericytes. This results in granular osmiophilic deposits, characteristic 
of disease. The deposits are toxic and impair blood flow, leading patients to 
develop vascular symptoms1,3,4. MRI is the best neuroimaging modality to 
investigate CADASIL1,2,5 (see figure 1). The diagnosis of CASDASIL should 
be considered when MRI characteristics are associated with typical clinical 
findings. Differential diagnosis of CADASIL includes multiple sclerosis, primary 
angiitis of the nervous system, sporadic small vessel disease including 
Binswanger’s disease, cerebral autosomal recessive arteriopathy with subcortical 
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infarcts and leukoencephalopathy (CARASIL), 
and some other forms of leukodystrophy1-5. There 
is no specific  treatment  for CADASIL. Antiplatelet 
agents such as aspirin might help to prevent new 
strokes. Other symptoms, like headache, seizures, 
or other neuropsychiatric manifestations, should be 
appropriately treated1,2,5.
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Figure 1: Magnetic resonance imaging fluid-attenuated inversion recovery (MRI-FLAIR) axial scans. Brain MRI-FLAIR axial 
scans showing lacunar infarcts and less-well demarcated hyperintensities characteristically located in the subcortical white 
matter (large white lesions). These white matter hyperintensities can be observed in anterior temporal lobe and occur in 
about 90% of patients with cerebral autosomal-dominant arteriopathy with subcortical infarcts and leukoencephalopathy 
(CADASIL).
REFERENCES
1. Rutten J, Lesnik Oberstein SAJ, 
editors. CADASIL. In: Pagon RA, 
Adam MP, Ardinger HH, Wallace SE, 
Amemiya A, Bean LJH, et al. editors. 
SourceGeneReviews®. Seattle: 
University of Washington; 1993.
2. Chabriat H, Joutel A, Dichgans M, 
Tournier-Lasserve E, Bousser MG. 




3. Tikka S, Baumann M, Siitonen M, 
Pasanen P, Pöyhönen M, Myllykangas 
L, et al. CADASIL and CARASIL. 
Brain Pathol. 2014;24(5):525-44. 
PMid:25323668. http://dx.doi.
org/10.1111/bpa.12181. 
4. Andersson ER, Lendahl U. 
Therapeutic modulation of Notch 
signalling: are we there yet? Nat 
Rev Drug Discov. 2014;13(5):357-
78. PMid:24781550. http://dx.doi.
org/10.1038/nrd4252. 
5. André C. CADASIL: pathogenesis, 
clinical and radiological findings 




Received: July 19, 2016 
Accepted: Dec 13, 2016
